Clinical Trials on Lung Adenocarcinoma in Argentina

Total 889 results

Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
GlaxoSmithKline

Terminated

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (AMBER II)

Hypertension

Spain, Germany, Korea, Republic of, Canada, Japan, Netherlands, United Kingdom, Czechia, United States, China, Austria, Israel, Argentina, Russian Federation, Mexico, Saudi Arabia
GlaxoSmithKline

Terminated

Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. (AMBER I)

Hypertension

Spain, Germany, Korea, Republic of, Canada, Japan, Netherlands, United Kingdom, United States, China, Austria, Israel, Argentina, Russian Federation, Mexico, Saudi Arabia, Czech Republic
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, Romania, Russian Federation, South Africa, Spain, Sweden, Thailand
Bristol-Myers Squibb

Active, not recruiting

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Russian Federation, Belgium, United States, Australia, Argentina, Brazil, Canada, China, Czechia, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Taiwan, United Kingdom
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Carcinoma, Non-Small-Cell Lung

Japan, China, Canada, Spain, Germany, Korea, Republic of, Austria, Brazil, Greece, France, United States, Italy, Argentina, Chile, Hungary, India, Turkey, Romania, Netherlands, Poland, Switzerland
Novartis Pharmaceuticals

Completed

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma (THUNDER)

Nasal Polyps

Germany, Belgium, Italy, Argentina, Canada, Netherlands, Czechia, Poland, United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

Nonsquamous Non-small Cell Lung Cancer

United States, Argentina, Australia, Canada, Chile, China, France, Germany, Israel, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, United Kingdom
AstraZeneca

Active, not recruiting

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)

Non Small Cell Lung Carcinoma NSCLC

Denmark, United Kingdom, United States, Poland, Brazil, India, Japan, Mexico, Peru, Russian Federation, Turkey, China, Malaysia, Hong Kong, Korea, Republic of, Chile, Israel, Ukraine, Portugal, Greece, Bulgaria, Philippines, Sweden, A... and more
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Asthma

Germany, United States, Belgium, Poland, Latvia, Argentina, Guatemala, Philippines, Slovakia, Czechia, Hungary, Russian Federation, Japan, Bulgaria, Canada
MedImmune LLC

Completed

A Safety and Efficacy Study of Tralokinumab in Adults With Asthma

Asthma

United States, Czech Republic, France, Korea, Republic of, Mexico, Poland, Russian Federation, Spain, United Kingdom, Germany, Philippines, Argentina, Canada, Chile, Japan
Amgen

Recruiting

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304)

Small Cell Lung Cancer (SCLC)

China, United States, Australia, Netherlands, Taiwan, Spain, Canada, Korea, Republic of, Turkey, Israel, Austria, Japan, France, United Kingdom, Germany, Belgium, Denmark, Czechia, Switzerland, Italy, Hungary, Ireland, Argentina, Brazil, Malays... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL)

Carcinoma, Non-Small-Cell Lung

Italy, Netherlands, Argentina, Brazil, China, Denmark, Greece, Panama, Spain, United Arab Emirates, United Kingdom, Mexico, Poland, Peru, Philippines, Costa Rica, Malaysia, Morocco, Latvia, Lebanon, Sweden, Slovenia, Colombia, Guatemala
GlaxoSmithKline

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (BLISSc-ILD)

Scleroderma, Systemic | Systemic Sclerosis Associated Interstitial Lung Disease

United States, Australia, France, Italy, Japan, Spain, Belgium, Greece, Korea, Republic of, China, Mexico, United Kingdom, Finland, Israel, Germany, Argentina, Brazil, Canada, Denmark
Bond Avillion 2 Development LP

Completed

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (DENALI)

Asthma

United States, Germany, Ukraine, Serbia, Czechia, Argentina, Slovakia
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma

Asthma

Germany, United States, South Africa, Hungary, Turkey, Slovakia, Argentina, Philippines, Mexico, Saudi Arabia
GlaxoSmithKline

Completed

Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Australia, Argentina, Japan, Russian Federation, Spain, Germany, Mexico, Romania, Korea, Republic of, Poland, Italy, France
GlaxoSmithKline

Completed

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (DREAM)

Asthma

United States, Argentina, Australia, Germany, Poland, Romania, Russian Federation, Ukraine, Canada, Chile, France, Korea, Republic of, United Kingdom
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)

Non-Small Cell Lung Cancer

Canada, Belgium, Korea, Republic of, United States, France, Brazil, China, New Zealand, Israel, Spain, Argentina, Serbia, Mexico, Italy, Japan, Turkey, Taiwan, Costa Rica, Thailand, Australia, Germany, Hong Kong, Netherlands, Peru, Poland, Russian Federation and more
Pfizer

Completed

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Carcinoma, Non-Small Cell Lung

United States, Netherlands, Canada, Belgium, Spain, United Kingdom, Greece, Germany, Korea, Republic of, Poland, Russian Federation, Denmark, Chile, Colombia, Hungary, Czech Republic, Italy, Thailand, Brazil, Hong Kong, Taiwan, Sl... and more
AstraZeneca

Active, not recruiting

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

Non-Small Cell Lung Cancer

Belgium, Italy, Spain, United States, Poland, India, Taiwan, Thailand, Vietnam, Canada, France, Germany, Korea, Republic of, Brazil, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation, China, Austria, Chile, Netherlands, Bulg... and more
GlaxoSmithKline

Active, not recruiting

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer (ZEAL-1L)

Lung Cancer, Non-Small Cell

Argentina, France, Spain, Italy, Belgium, Korea, Republic of, United States, Mexico, Hungary, Sweden, Turkey, Ireland, Greece, Russian Federation, Germany, Netherlands, Bulgaria, Romania, Brazil, United Kingdom, Poland, Australia, C... and more
Bayer

Terminated

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small Cell Lung

Belgium, Italy, Spain, Hong Kong, United States, Germany, United Kingdom, Chile, Taiwan, Australia, Canada, Argentina, Puerto Rico, France, Poland, Russian Federation, Sweden, Hungary, Netherlands, Brazil, Korea, Republic of
Eli Lilly and Company

Completed

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

United States, China, Italy, Australia, Spain, Germany, Belgium, United Kingdom, Hungary, Taiwan, Austria, France, Poland, Greece, Netherlands, Brazil, India, Romania, Turkey, Russian Federation, Argentina, South Africa, Korea, Republic... and more
PureTech

Active, not recruiting

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ELEVATE)

Idiopathic Pulmonary Fibrosis

Thailand, United States, Korea, Republic of, Philippines, Greece, Georgia, Malaysia, Mexico, Chile, Argentina, Colombia, India, South Africa, Romania
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

Taiwan, Hong Kong, United States, Netherlands, United Kingdom, Italy, Korea, Republic of, Spain, Israel, Japan, France, Portugal, China, Turkey, Brazil, Mexico, Austria, Germany, Belgium, Chile, Argentina, Singapore, Canada
AstraZeneca

Completed

Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide® (SPEED)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil, United Kingdom, Germany, Philippines, Denmark, Australia, Argentina, India, Belgium
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

United States, Spain, France, Australia, Germany, Taiwan, Canada, Argentina, Belgium, Singapore, Brazil, Netherlands, Israel, Portugal, Russian Federation, Japan, Italy, Chile, Latvia, Peru, Ukraine, Lithuania, Slovakia, Bulgaria, Mexico, Austri...
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)

Hepatocellular Carcinoma

Germany, Romania, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Hong Kong, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland and more
Novartis Pharmaceuticals

Completed

Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (INSTEAD)

Chronic Obstructive Pulmonary Disease

Colombia, Italy, Switzerland, Argentina, United Kingdom, Mexico, Netherlands, Malaysia, Spain
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Hepatocellular Carcinoma | Hepatoma | Liver Cell Carcinoma | Liver Cancer, Adult | Liver Cell Carcinoma, Adult

Chile, Brazil, Argentina, China, Czechia, France, Hong Kong, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Singapore, Spain, Taiwan, Turkey
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
BioAge Labs, Inc.

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

Covid19

United States, Brazil, Argentina
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
Boehringer Ingelheim

Completed

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

Lung Diseases, Interstitial

United States, Spain, United Kingdom, Belgium, Australia, Germany, India, Israel, Thailand, China, Japan, Malaysia, France, Austria, Greece, Norway, Netherlands, Switzerland, Chile, Denmark, Finland, Portugal, Argentina, Brazil, Canada, C... and more
AstraZeneca

Active, not recruiting

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) (CASPIAN)

Small Cell Lung Carcinoma Extensive Disease

Germany, United States, Poland, Taiwan, Turkey, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, China, Netherlands, Spain, Israel, Ukraine, Austria, France, Bulgaria, Romania, Argentina, Slovakia
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation
COVID-19 Prevention Network
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study of Immune Responses to the Virus That Causes COVID-19 (CoVPN 5001)

COVID-19 | SARS-CoV-2

United States, Malawi, Zimbabwe, Botswana, South Africa, Zambia, Argentina, Brazil, Mexico, Peru, Tanzania
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011)

Renal Cell Carcinoma

United States, Argentina, Brazil, Canada, France, Germany, Mexico, Russian Federation
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
Hoffmann-La Roche
Atea Pharmaceuticals, Inc.

Terminated

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 (MORNINGSKY)

COVID-19

Switzerland, Turkey, Denmark, Belgium, Japan, Mexico, Argentina, Brazil, Germany, Portugal, Romania, Ukraine
AstraZeneca

Completed

Iressa Versus Docetaxel (Taxotere)

Non-Small-Cell Lung Carcinoma

United States, Croatia, Sweden, Italy, Mexico, Spain, Turkey, Germany, Philippines, Malaysia, China, Estonia, Latvia, Hong Kong, Argentina, Belgium, Canada, Denmark, France, Indonesia, Thailand, Brazil, Switzerland, Singapore, Slovenia
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

Small Cell Lung Carcinoma

United States, Poland, Israel, Argentina, Australia, Austria, Canada, China, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, Portugal, Romania, Spain, Turkey, United...
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (CheckMate 451)

Lung Cancer

Australia, China, Romania, Colombia, Ireland, Israel, Japan, Spain, Peru, United States, Brazil, Greece, Singapore, Argentina, Austria, Belgium, Canada, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Mexico, Netherlands, ... and more
Novartis Pharmaceuticals

Terminated

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer (ATRACT-1)

Non-Small Cell Lung Cancer

United States, Greece, Hong Kong, Taiwan, Argentina, Germany, United Kingdom, Singapore, Italy, Spain, France, Korea, Republic of, Netherlands, Brazil, Canada, Turkey, China, New Zealand, Hungary, Poland, Australia, Japan, Israel, Bel... and more
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

Non-small Cell Lung Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Estonia, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Poland, Romania, Russian Federation, South Africa, Spain, Taiwan, U... and more
GlaxoSmithKline

Recruiting

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma

Asthma

United States, Italy, Panama, Spain, Canada, Poland, Australia, Argentina, France, Greece, Philippines, Thailand, United Kingdom

Clinical Trials on Lung Adenocarcinoma in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations